Detailed information for compound 186204

Basic information

Technical information
  • TDR Targets ID: 186204
  • Name: (2R,3R,4S)-4-(1-benzofuran-6-yl)-1-[2-(dibuty lamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrol idine-3-carboxylic acid
  • MW: 506.633 | Formula: C30H38N2O5
  • H donors: 1 H acceptors: 3 LogP: 2.97 Rotable bonds: 13
    Rule of 5 violations (Lipinski): 2
  • SMILES: CCCCN(C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(cc1)OC)C(=O)O)c1ccc2c(c1)occ2)CCCC
  • InChi: 1S/C30H38N2O5/c1-4-6-15-31(16-7-5-2)27(33)20-32-19-25(23-9-8-21-14-17-37-26(21)18-23)28(30(34)35)29(32)22-10-12-24(36-3)13-11-22/h8-14,17-18,25,28-29H,4-7,15-16,19-20H2,1-3H3,(H,34,35)/t25-,28-,29+/m1/s1
  • InChiKey: WHDVQUAEJOXCTD-ZJGIAAPESA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2R,3R,4S)-4-(benzofuran-6-yl)-1-[2-(dibutylamino)-2-oxo-ethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
  • (2R,3R,4S)-4-(6-benzofuranyl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid
  • (2R,3R,4S)-4-(1-benzofuran-6-yl)-1-[2-(dibutylamino)-2-oxo-ethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
  • (2R,3R,4S)-4-(benzofuran-6-yl)-1-[2-(dibutylamino)-2-keto-ethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Endothelin receptor ET-A Starlite/ChEMBL References
Sus scrofa Endothelin receptor ET-B Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Onchocerca volvulus Endothelin receptor ET-B   443 aa 371 aa 20.5 %
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Endothelin receptor ET-B   443 aa 392 aa 23.5 %
Echinococcus multilocularis pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 21.1 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 20.1 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni NADP-specific isocitrate dehydrogenase 0.1068 0.5 0.5
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1068 0.5 0.5
Leishmania major isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1068 0.5 0.5
Trypanosoma brucei isocitrate dehydrogenase, putative 0.1068 0.5 0.5
Trypanosoma cruzi isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1068 0.5 0.5
Echinococcus granulosus NADP dependent isocitrate dehydrogenase 0.1068 0.5 0.5
Trypanosoma brucei isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1068 0.5 0.5
Plasmodium vivax isocitrate dehydrogenase [NADP], mitochondrial, putative 0.1068 0.5 0.5
Trypanosoma cruzi isocitrate dehydrogenase, putative 0.1068 0.5 0.5
Mycobacterium tuberculosis Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) 0.1068 0.5 0.5
Toxoplasma gondii isocitrate dehydrogenase 0.1068 0.5 0.5
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1068 0.5 0.5
Plasmodium falciparum isocitrate dehydrogenase [NADP], mitochondrial 0.1068 0.5 0.5
Toxoplasma gondii isocitrate dehydrogenase 0.1068 0.5 0.5
Echinococcus multilocularis isocitrate dehydrogenase 2 (NADP+) 0.1068 0.5 0.5
Loa Loa (eye worm) isocitrate dehydrogenase 0.1068 0.5 0.5
Brugia malayi Isocitrate dehydrogenase 0.1068 0.5 0.5
Echinococcus multilocularis isocitrate dehydrogenase 0.1068 0.5 0.5
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1068 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
AUC (ADMET) = 370 ug min ml-1 Area under curve was determined in carotid blood of rat when administered intradermally ChEMBL. 9022798
AUC (ADMET) = 540 ug min ml-1 Area under curve was determined in portal blood of rat when administered intradermally ChEMBL. 9022798
Cmax (ADMET) = 4.7 ug ml-1 Maximum concentration of compound in plasma administered orally to rats ChEMBL. 9022798
F (ADMET) = 38 % Oral bioavailability in rat ChEMBL. 9022798
IC50 (binding) = 0.0007 uM Binding affinity towards endothelin A receptor in prolactin secreting rat pituitary cells using [125I]-ET-1 as radioligand. ChEMBL. 9022798
IC50 (binding) = 0.0007 uM Binding affinity towards endothelin A receptor in prolactin secreting rat pituitary cells using [125I]-ET-1 as radioligand. ChEMBL. 9022798
IC50 (binding) = 5 uM Binding affinity towards endothelin B receptor in porcine cerebellar tissue using [125I]-ET-1 as radioligand. ChEMBL. 9022798
IC50 (binding) = 5 uM Binding affinity towards endothelin B receptor in porcine cerebellar tissue using [125I]-ET-1 as radioligand. ChEMBL. 9022798
T1/2 (ADMET) = 4.7 hr Time taken to decrease the plasma concentration to half of the maximum concentration when compound was administered intravenously in rats ChEMBL. 9022798

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.